INTRODUCTION AND OBJECTIVES: Acute urinary retention (AUR) patients nonresponsive to alpha blockade have limited treatment options to restore voiding and have been commonly excluded from clinical trials examining efficacy of minimally invasive technology. This study assessed feasibility of the Prostatic Urethra Lift (PUL) in patients with AUR secondary to benign prostate obstruction.
METHODS: AUR male subjects (! 50 years of age) diagnosed with symptomatic BPH and at least one failed trial without catheter (TWOC) while on alpha blocker were enrolled in the study. Subjects with retention volumes >1500mL were excluded. Void trials were performed 3 days post-procedure, and symptom response (IPSS), quality of life (QoL), BPH Impact Index (BPHII), peak flow rate (Qmax) and post void residual (PVR) were assessed at 6-week follow-up. Percent of successful first TWOC and time to catheter independence was calculated. Incidence of related adverse events and surgical interventions were analyzed and summarized descriptively.
RESULTS: This preliminary analysis included 30 males (mean age of 73 years) who received PUL across 4 sites in the United Kingdom. Mean prostate volume at baseline was 56.9cc and mean duration of the most recent retention episode prior to PUL was 83.4 days. Furthermore, 66.7% of subjects failed two or more TWOCs before the procedure. Although baseline symptom response and uroflowmetry assessments were not available due to retention status, mean IPSS (9.7), QoL (1.3), BPHII (1.8) and Qmax (8.7ml/s) and PVR (112.1ml) were recorded at 6-week follow-up (Table 1) . Compared to L.I.F.T 3-month unpaired outcomes, AUR subjects demonstrated similar IPSS, BPHII and PVR, but lower QoL and lower Qmax scores (Table 1 , p < 0.05). 63.3% of AUR subjects were able to void without a catheter and 70% were catheter free by 1 month. The majority of adverse events were mild to moderate and resolved by two weeks. One subject experienced a UTI and two subjects experienced hematuria events that were serious but resolved by two weeks. One subject underwent a HoLEP 114 days post-procedure.
CONCLUSIONS: PUL offers AUR patients an alternative to long-term catheter management and invasive treatment options. This approach can quickly and safely restore spontaneous micturition in this patient population.
Source of Funding: Neotract/Teleflex Inc.
PD24-10 THE CLINICAL EFFICACY OF PROLONGED RELEASE MELATONIN ON NOCTURIA WITH ELDERLY PATIENTS
Sun Tae Ahn*, Dong Hyun Lee, Hyeong Guk Jeong, Sang Woo Kim, Jong Wook Kim, Du Geon Moon, Seoul, Korea, Republic of INTRODUCTION AND OBJECTIVES: In elderly, age-related changes in sleep depth and continuity affect normal circadian rhythm and the normal circadian pattern of micturition as well. Although it seems logical that use hypnotics for improving sleep quality and desmopressin for decreasing nocturnal urine output, they increase the potential risk of dependency and side effects in elderly. Thus we herein investigated the efficacy and safety of melatonin, an antioxidant and sleep inducer free of addiction, on treatment of nocturia in elderly patients as a pilot study.
METHODS: The study was conducted prospectively and enrolled male patients over 55 years old who had two or more episode of nocturia per night. Melatonin 2mg (Circadin Ò ) was administered orally 2-3 hours before bedtime for 12 weeks. All patients were assessed the Pittsburgh Sleep Quality Index (PSQI) and frequency volume (FV) chart at baseline and 12 weeks after starting melatonin. RESULTS: Overall, 50 patients were completed the study. Total of 30 of them (60%) showed poor sleep quality (SQ) defined as a score of 6 or more on the PSQI global score at baseline. In this group global PSQI score significantly improved (from 10.5AE2.9 to 7.2AE4.0, p[0.01) whereas 20 patients (40%) with good SQ did not (from 3.3AE1.4 to 4. 4AE2.9, p[0.198) . The number of nocturia episodes significantly decreased in poor SQ group and superior to good SQ group. (Figure. 1) Changes of other FV chart values in patient with poor SQ group and good SQ group were presented in Table 1 . Three patients had dizziness; the remaining patients had no adverse drug-related events.
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